Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
On August 19, 2021, at 07:00 CEST, Calliditas Therapeutics published its interim report for the second quarter 2021.
Audio cast with teleconference, Q2 2021, August 19, 2021, 14:30 (Europe/Stockholm)
Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden
Company number: 556659-9766
© Calliditas Therapeutics AB 2021